<DOC>
	<DOCNO>NCT01207648</DOCNO>
	<brief_summary>The aim retrospective study review describe safety , tolerability efficacy Rebif® ( subcutaneous interferon [ IFN ] -beta-1a ) child adolescent , use information already record medical record . The study duration 13 July 2010 ( first data collect ) 13 July 2011 ( last data collect ) . In study , Data subject evaluate 1997 2009 observe .</brief_summary>
	<brief_title>Retrospective Cohort Study Rebif® Use Pediatric Multiple Sclerosis ( MS ) Subjects ( REPLAY )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Received one injection Rebif® treatment demyelinate event Be young 18 year age time Rebif® treatment initiation Rebif® therapy must initiate June 30 , 2009 No exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Interferon beta 1a</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>Demyelinating Diseases</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Demyelinating Autoimmune Diseases , CNS</keyword>
	<keyword>Autoimmune Diseases Nervous System</keyword>
	<keyword>Retrospective Cohort Study</keyword>
</DOC>